IONIS-AGT-LRx

DRUG2 trials

Sponsors

Ionis Pharmaceuticals, Inc.

Conditions

Chronic Heart Failure With Reduced Ejection FractionHypertension

Phase 2

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure

CompletedNCT04714320

Ionis Pharmaceuticals, Inc.Hypertension

Start: 2021-04-28End: 2022-10-03Updated: 2025-02-18

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction

CompletedNCT04836182

Ionis Pharmaceuticals, Inc.Chronic Heart Failure With Reduced Ejection Fraction

Start: 2021-06-08End: 2023-01-11Updated: 2023-09-11

Related Papers

Antisense Inhibition of Angiotensinogen With IONIS-AGT-L<sub>Rx</sub>: Results of Phase 1 and Phase 2 Studies.

2021-05-0352 citations